Christiansen N P, Kennedy B J, Ochoa A C, Skubitz K M, Bach F H
Division of Medical Oncology, University of Minnesota Medical School, Minneapolis.
Med Pediatr Oncol. 1989;17(6):455-8. doi: 10.1002/mpo.2950170521.
Adoptive immunotherapy with recombinant interleukin-2 (rIL-2) and lymphokine-activated killer (LAK) cells has been reported to effect the regression of tumor in patients with a variety of malignancies. Responses have occurred in patients treated with high-dose bolus rIL2 as well as lower-dose continuous intravenous infusion. Ten patients who had been extensively pretreated with systemic chemotherapy with or without additional radiation therapy were treated with continuous infusion rIL2 and LAK cells. Five patients received rIL2 alone for 96-120 hours prior to leukapheresis in addition to rIL2 at the time of LAK cell infusion. Three patients received LAK cells that had been cultured for 14 days in an automated tissue culture system. No responses were seen in this ten-patient cohort. While the lack of response in these patients may be related to any one or more of several variables, patients who have been heavily pretreated may not respond as well as patients who have received little to no systemic chemotherapy.
据报道，采用重组白细胞介素-2（rIL-2）和淋巴因子激活的杀伤细胞（LAK）进行过继性免疫疗法可使多种恶性肿瘤患者的肿瘤消退。接受大剂量推注rIL-2以及小剂量持续静脉输注治疗的患者均有反应。10例曾接受过全身化疗（有或无额外放疗）的患者接受了rIL-2持续输注及LAK细胞治疗。5例患者在采集白细胞前单独接受rIL-2治疗96 - 120小时，此外在输注LAK细胞时也使用rIL-2。3例患者接受了在自动组织培养系统中培养14天的LAK细胞。在这个10例患者的队列中未观察到反应。虽然这些患者缺乏反应可能与几个变量中的任何一个或多个有关，但接受过大量预处理的患者可能不如接受很少或未接受全身化疗的患者反应好。
